Exelixis | EXEL - Pre Tax Profit

Stock Price
43.93
Daily Change
1.56 3.68%
Monthly
-4.89%
Yearly
31.21%
Q1 Forecast
40.09

Exelixis reported $252.41M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 44.6M 4.38M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
AstraZeneca USD 3.24B 117M Sep/2025
Bayer EUR -1.16B 735M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Eisai JPY 14.53B 7.87B Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Exelixis USD 252.41M 22M Sep/2025
Genmab DKK 482M 59M Sep/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 482.31M 75.7M Sep/2025
Ionis Pharmaceuticals USD -129M 253M Sep/2025
MacroGenics USD 16.82M 52.97M Sep/2025
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Sanofi EUR -1.16B 6.23B Dec/2025
Takeda JPY 133.86B 105.69B Dec/2025
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
Xencor USD -6.03M 25.05M Sep/2025